{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE325nnn/GSE325262/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE325262"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Targeting ABL kinases to overcome melanoma immune evasion during MAPKi resistance","description":"We utilized single-cell sequencing to determine the mechanism by which the ABL1/2 inhibitor, nilotinib, prevents the onset of BRAF/MEK inhibitor resistance. Mice harboring mouse melanomas were treated with BRAF/MEK inhibitors or BRAF/MEK inhibitors plus nilotinib for 4 days, and the resulting tumors were subjected to single-cell RNA-sequencing in order to assess changes in the melanoma and immune populations.","dates":{"publication":"2026/07/23"},"accession":"GSE325262","cross_references":{"GSM":["GSM9598703","GSM9598702"],"GPL":["17021"],"GSE":["325262"],"taxon":["Mus musculus"]}}